PINK:ENZC

Enzolytics Stock News

Healthcare > Biotechnology

Buy ENZC

*Your capital is at risk

$0.0006

+0.00005 (+9.09%)

At Close: Jul 31, 2026

Enzolytics Announces the Signing of the Business Combination Agreement with Sagaliam Acquisition Corp (SAGA)

08:00am, Monday, 18'th Sep 2023

COLLEGE STATION, TX / ACCESSWIRE / September 18, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com). Enzolytics, Inc. announces today that it has executed the binding business combinatio

Patient Population for the Clinical Trials of ITV-1 has been Established by the European Medicines Agency ("EMA")

08:45am, Wednesday, 06'th Sep 2023

Start date is expected by the end of 2023 / beginning of 2024. VIRO also offers an update on Diabetic trials and Sagaliam transaction.

Biogenysis, Inc. Announces Partnering with Khalpey AI Lab and Contenta, Ltd. to Incorporate AI in Microbiome Analysis to Identify Biomarkers for Use in Accurately Predicting Alzheimer's Disease Onset and Prevention.

08:00am, Tuesday, 05'th Sep 2023

COLLEGE STATION, TX / ACCESSWIRE / September 5, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Biogenysis, Inc. ("BGEN"), a wholly owned subsidiary of Enzolytics, Inc. (the "Compan

Biogenysis' International Patent Application, Covering Its Anti-SARS-CoV-2 Monoclonal Antibodies, Advances to Prosecution in Europe and as a U.S. National Stage Application.

08:00am, Thursday, 24'th Aug 2023

COLLEGE STATION, TX / ACCESSWIRE / August 24, 2023 / Biogenysis, Inc. (OTC PINK:ENZC) (or the "Company"). Biogenysis, a subsidiary of Enzolytics, Inc., announces the progress of its Patent Cooperation

Virogentics, Inc. Receives Permit for Export to Africa of the ITV-1 Immunotherapy Solidifying the Scheduled Administration of the Treatment

01:00pm, Tuesday, 08'th Aug 2023

Reports on Business combination agreement progress ALLEN, TX / ACCESSWIRE / August 8, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Virogentics, Inc. ("VIRO") a wholly owned subsi

Virogentics, Inc. Provides Update on African Project, European Medicine Agency Application and Clinical Trials for Application for Type 2 Diabetes

09:30am, Friday, 04'th Aug 2023

Progress on Sagaliam Acquisition Corp Transaction ALLEN, TX / ACCESSWIRE / August 4, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Virogentics, Inc. ("VIRO"), a wholly owned subsi

CORRECTION FROM SOURCE: Virogentics Announces Approval of Final Protocol from the Dept for HIV and AIDS, Ministry of Health of the DRC

02:00pm, Monday, 24'th Jul 2023

Expects to Issue Update on EMA Progress ALLEN, TX / ACCESSWIRE / July 24, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). CORRECTED Virogentics, Inc. ("VIRO") a wholly owned subsidi

Virogentics, Inc to Introduce a Dietary Supplement Offers Additional Information on ITV-1 and Diabetic Clinical Trials

08:55am, Monday, 24'th Jul 2023

ALLEN, TX / ACCESSWIRE / July 24, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Virogentics, Inc. ("VIRO") a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC"),

Biogenysis Inc. Announces a Collaboration with Khalpey AI Lab in using Artificial Intelligence (AI) for Unveiling Potential Biomarkers and Predicting the Onset or Prevention of Alzheimer's Disease.

07:00am, Friday, 21'st Jul 2023

COLLEGE STATION, TX / ACCESSWIRE / July 21, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Biogenysis, Inc. ("BGEN"), a wholly owned subsidiary of Enzolytics, Inc. (the "Company" o

Enzolytics Inc. Files Supplemental Information Report on the Sale of Biogenysis, Inc. and Virogentics, Inc to Sagaliam Acquisition Corp.

10:05am, Tuesday, 11'th Jul 2023

COLLEGE STATION, TX / ACCESSWIRE / July 11, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Enzolytics, Inc. ("ENZC" or the "Company") filed a Supplemental Information report today

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by